REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical va...
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05628857
- Locations
- 🇨🇳
Beijing Cancer Hopspital, Beijing, Beijing, China
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05514158
- Locations
- 🇨🇳
Remegen, Beijing, Beijing, China
A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT05508334
- Locations
- 🇨🇳
Remgenen, Beijing, Beijing, China
🇨🇳Remegen, Beijing, Beijing, China
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT05306574
- Locations
- 🇬🇹
Guatemala site, Guatemala, Guatemala
🇺🇸Orange Site, Orange, California, United States
🇲🇺Quatre Bornes Site, Quatre Bornes, Mauritius
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 452
- Registration Number
- NCT05302284
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05297552
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT05247203
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Xiangya Hospital, Central South University, Changsha, Hunan, China
A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT05205850
- Locations
- 🇨🇳
The first affiliated hospital, zhejiang universtity school of medicine, Hangzhou, Zhejiang, China
🇨🇳Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
- Conditions
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05135715
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Zhejiang cancer hospital, Hangzhou, Zhejiang, China
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04965519
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China